Partial ectogestation continues to move towards human clinical trials. This article draws upon the Report of the Committee of Inquiry into Human Fertilisation and Embryology (Warnock Report) to provide guidance as to what may need to be considered for the future regulation of this technology. While the Warnock Report dates back to 1984, its significance and legacy continue to influence the current regulation of reproductive practices in the UK. By drawing upon specific elements within the report, many of the decisions and recommendations within it could provide direction for the future regulation of partial ectogestation. The role of the public, the social and political context at the time of the Warnock report, the determination of the status of the embryo, and arguments pitted against in vitro fertilisation (IVF) at the time, are all examined. As a result, this article suggests that the inclusion of the general public in the development and implementation of partial ectogestation prior to another Warnock-style inquiry will increase the success of long-standing regulatory and legislative provisions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/medlaw/fwad008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Food Policy Councils and Healthy Food Access Policies: A 2021 National Survey of Community Policy Supports.
Prev Chronic Dis
January 2025
Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Introduction: Food policy councils (FPCs) are frequently used to facilitate change in food systems at the local, state, and regional levels, or in tribal nations. The objective of this study was to describe the prevalence of food policy councils and similar coalitions among US municipalities and their associations with healthy food access policies.
Methods: We used data from the 2021 National Survey of Community-Based Policy and Environmental Supports for Healthy Eating and Active Living, administered to municipal officials from May through September 2021.
Defective kinase activity of IKKα leads to combined immunodeficiency and disruption of immune tolerance in humans.
Nat Commun
November 2024
Can Sucak Research Laboratory for Translational Immunology, Hacettepe University, Ankara, Türkiye.
IKKα is a multifunctional serine/threonine kinase that controls various biological processes, either dependent on or independent of its kinase activity. However, the importance of the kinase function of IKKα in human physiology remains unknown since no biallelic variants disrupting its kinase activity have been reported. In this study, we present a homozygous germline missense variant in the kinase domain of IKKα, which is present in three children from two Turkish families.
View Article and Find Full Text PDFMedications for opioid use disorder and other evidence-based service offerings in faith-affiliated treatment centers: Implications for implementation partnerships.
J Subst Use Addict Treat
November 2024
Yale School of Public Health, Department of Social and Behavioral Sciences, United States of America.
Article Synopsis
- Clinicians and policymakers are looking to collaborate with faith-affiliated treatment centers (FATCs) to improve access to effective treatments for opioid use disorder (OUD), but there's limited knowledge about how these centers compare to non-faith-based ones in offering evidence-based services.
- An analysis using the 2021 National Substance Use and Mental Health Services Survey found that FATCs generally provide fewer medication options for opioid use disorder (MOUD) and are less inclined to accept clients using MOUD, while they tend to offer more residential treatment and transitional housing.
- The study highlights the need for further research to understand the reasons behind these differences and emphasizes the importance of aligning the goals of clinicians and policymakers with the values of FATCs when forming
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
J Inherit Metab Dis
January 2025
Division of Medical Genetics and Genomics, Stead Family Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA.
Article Synopsis
- Pegunigalsidase alfa is a new enzyme replacement therapy for Fabry disease, showing a longer half-life and administered every 4 weeks instead of the typical 2-week schedule.
- The BRIGHT study involved 30 adult patients who switched from another ERT to pegunigalsidase alfa, revealing good safety results with mostly mild side effects and no new anti-drug antibodies.
- Although the treatment showed acceptable tolerance, more research is needed due to the small sample size, but it suggests that this 4-week regimen could be a viable new option for managing Fabry disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!